Inverna
Invenra accelerates your next-generation antibody discovery by specializing in rapid bispecific, trispecific and multispecific antibody development using our clinically validated B-Body™ and T-Body™ platforms.
The B-Body™ and T-Body™ systems address common challenges in multispecific development—including expression yields, stability, and purification complexity—while maintaining the flexibility to accommodate diverse target combinations and therapeutic modalities. Our Fab-based technologies integrate engineered specificity with manufacturing compatibility, enabling streamlined workflows that deliver optimized bispecific antibodies in four months from partner antigens or two months from existing monoclonal antibody panels.
If you’re advancing bi- or tri-specific therapeutics, Invenra is ready to dramatically speed up your discovery and development pipeline.
